Ms Martine Gaetan

Martine Gaetan


Healthcare & Life Sciences

FDA issues draft guidance on clinical research of cannabis and cannabis-related products
USA | 05 August 2020

The US Food and Drug Administration recently issued its draft guidance on clinical research for the development of drugs that contain cannabis or cannabis-derived compounds of botanical origin (as opposed to synthetic). The guidance provides some clarity on the use of cannabis in clinical research in light of the changes made by the Agriculture Improvement Act 2018, which federally legalised hemp and derivatives that contain no more than 0.3% by dry weight of THC.